Skip to main content

Endocrinology & Diabetes

We offer patients and their relatives several opportunities to participate in clinical research trials and to support our basic-science, clincial and educational work.

These studies are always reviewed and approved by the Office of Research Ethics of the University of British Columbia and the BC Children's Hospital Research Institute.

At present, we are enrolling subjects for studies in the following areas:


Blood/tissue registry for cellular mechanisms of childhood autoimmunity

We are currently recruiting patients more than 12 months of age with type 1 diabetes diagnosed within the last 6 months. Type 1 diabetes develops when the body's own immune system attacks and ultimately destroys the beta cells in the pancreas. These beta cells are responsible for making insulin, which is required for regulating blood sugar levels. The underlying reason why the immune system attacks the pancreatic beta cells is unknown. The cells of the immune system that attack the beta cells are called T cells. Scientific studies in mice have shown that the autoreactive T cells recognize a protein (known as an epitope) on the beta cells. When T cells recognize a specific epitope on the beta cell, they attack the cell, leading to its destruction. It is hypothesized that similar beta cell epitopes in humans with type 1 diabetes are also recognized by T cells. The purpose of this study is to identify human beta cell epitopes that trigger harmful T cell responses. Determining the proteins that cause T-cells to attack and destroy the beta cells will help scientists develop new therapies, preventions and diagnostic tests for type 1 diabetes.

Interested participants are invited to provide a one-time blood sample (between 2–4 teaspoons depending on age).

If you are interested in participating, please contact Ben Mammon at 604-875-2345, x4801 for more information.

Diabetes TrialNet: Natural history study of the development of type 1 diabetes

The Type 1 Diabetes TrialNet, an international research program, is screening relatives of people with type 1 diabetes to find out if these family members are at risk of developing diabetes. The screening test is the first phase of the TrialNet Natural History Study of the Development of Type 1 Diabetes "Pathway to Prevention". ( Identifier NCT00097292).

Screening involves either one or two blood tests to see if diabetes-related autoantibodies are present. Autoantibodies are proteins made by the body's immune system which indicate that the cells in the pancreas that make insulin may be damaged. There is no cost to you for these screening tests. You will be notified of results within 4–6 weeks after your blood sample is received.

If your or your child's test shows evidence of autoantibodies, you have the option of volunteering to be monitored every 6 months for the development of type 1 diabetes.

To be eligible to participate, you must be between 1–45 years of age, and you must be a first-degree relative (sibling, parent or child) of a person with type 1 diabetes. You may also participate if you are 20 years of age or less and are a second-degree relative (niece, nephew, aunt, uncle, cousin, or half-siblings) of a person with type 1 diabetes.

For more information, please contact Ben Mammon at 604-875-2345, x4801 or visit the TrialNet website.

Living with type 1 diabetes in adolescence and early adulthood

If you have type 1 diabetes, are between 14 and 24 years of age, and live in Canada, we would like to have your opinion about what it is like to live with diabetes. We invite you to complete an on-line questionnaire. Contact us on our website or by e-mail

Transition to adult care for young with type 1 diabetes

The purpose of this study is to determine whether a transition clinic for young adults where both the pediatric and adult health care providers are present will make improve the transition experience for adolescents and young adults with T1D. The results of this study will be used to advocate for health services that better serve the needs of young people with diabetes who are transitioning from pediatric to adult diabetes care.

What do I have to do if I choose to participate? Participation involves completing surveys at time of transition and 1 year after transition. The surveys can be completed online (on a computer at home) or on paper. Some questions in the baseline surveys ask about your transition readiness, and your well-being (e.g. energy, emotions) as well your emotions and feelings. One year after you transition from pediatric to adult care, you will complete another online survey to evaluate your transition experience.

All surveys will take approximately 25 minutes to complete. You will not be asked to provide any blood samples. The research team will access your health record from the last year to get information about different aspects of your care (e.g. number of clinic visits, number of hospital admission, A1C level etc.).

Eligibility: You are eligible to participate in this study if you are 17 years of age or older, have T1D, are followed at BC Children’s Hospital or Abbotsford Regional Hospital and have been identified by the diabetes team as a candidate for transition to adult care during the study period.

Compensation: In appreciation for your participation, you will receive a total of $50 in gift cards. The first gift card for $25 will be mailed to you after completion of the baseline surveys, and another gift card for $25 after you have completed the follow up surveys 1 year after transitioning to adult care. You will be give the option to pick your gift card from various choices such as Amazon, Cineplex or Indigo.

If you would like to participate or have any question please contact: Ms. Shelly Keidar at or by phone 604-875-2000, x6511.


No studies at this time.


No studies at this time.

SOURCE: Endocrinology & Diabetes ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Children's Hospital. All Rights Reserved.

    Copyright © 2022 Provincial Health Services Authority.